SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Akero Therapeutics, Inc. - AKRO
NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Akero Therapeutics, Inc. (“Akero” or the “Company”) (NASDAQ: AKRO).
- NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Akero Therapeutics, Inc. (“Akero” or the “Company”) (NASDAQ: AKRO).
- The investigation concerns whether Akero and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
- In addition, Akero added that 12 patients, including 11 in EFX groups, discontinued the trial due to drug-related adverse events.
- Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.